Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Recombinant factor VIIa (rFVIIa) is crucial for managing bleeding in hemophilia patients.
• A biosimilar version, AryoSeven, has been developed to potentially offer a generic alternative to NovoSeven.
• Understanding the activation profiles of these agents with prothrombin complex concentrates (PCCs) is essential for clinical application.

Purpose of the Study:

• To compare the activation profiles of NovoSeven and its biosimilar AryoSeven.
• To investigate the thrombin generation capacity of rFVIIa preparations when combined with different PCCs.
• To assess the comparability of NovoSeven and AryoSeven in activating PCCs.

Main Methods:

• Two commercially available PCCs, Profilnine and Beriplex, were utilized.
• The activation of PCCs by RecombiPlasTin 2G was assessed.
• The effect of adding rFVIIa (NovoSeven and AryoSeven) at varying concentrations (0.25-0.5 µg/mL) on PCC activation and thrombin generation was analyzed.
• Prothrombin to thrombin conversion was monitored over time.

Main Results:

• Profilnine activated by RecombiPlasTin 2G showed prothrombin to prethrombin and thrombin conversion within 5-30 minutes.
• Addition of rFVIIa to Profilnine and RecombiPlasTin 2G resulted in complete prothrombin conversion to thrombin.
• Beriplex alone or with rFVIIa did not generate thrombin, but was fully activated by RecombiPlasTin 2G.
• Both NovoSeven and AryoSeven demonstrated similar activation patterns with the tested PCCs.

Conclusions:

• The activation of PCCs by both NovoSeven and AryoSeven leads to comparable thrombin generation.
• These findings suggest that AryoSeven exhibits a similar activation profile to NovoSeven when interacting with PCCs.
• The comparable activation profiles support the potential clinical utility of AryoSeven in hemophilia treatment.